Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.

Uchimiak, Katarzyna; Badowska-Kozakiewicz, Anna M; Sobiborowicz-Sadowska, Aleksandra; Deptala, Andrzej

Uchimiak, Katarzyna; Badowska-Kozakiewicz, Anna M; Sobiborowicz-Sadowska, Aleksandra; Deptala, Andrzej.

Afiliação

Uchimiak K; Students' Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland.
Badowska-Kozakiewicz AM; Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland.
Sobiborowicz-Sadowska A; Students' Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland.
Deptala A; Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland.

Clin Med Insights Oncol ; 16: 11795549221099869, 2022.

Article em En | MEDLINE | ID: mdl-35721387

Palavras-chave

Triple-negative breast cancer; atezolizumab; immune checkpoint inhibitors; immunotherapy; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Clin Med Insights Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google